Regulatory Filings • Jun 18, 2018
Regulatory Filings
Open in ViewerOpens in native device viewer
BerGenBio: Posters presented at Congress of European Hematology Association (EHA)
Bergen, Norway, 18 June 2018 - BerGenBio ASA (OSE:BGBIO) announces that the
company and its collaborators presented interim data from its Phase II clinical
development programme with bemcentinib, a selective, oral AXL inhibitor, in
acute myeloid leukaemia (AML) and myeloid dysplastic syndrome (MDS) as well as
biomarker data at the 23rd Congress of the European Hematology Association (EHA)
in Stockholm (14-17 June 2018).
The Company's academic collaborators at the University of Bergen, Haukeland
University Hospital (Bergen) presented a preclinical study investigating the
involvement of AXL in mantle cell lymphoma (MCL), and of bemcentinib to be a
potential new treatment option for this aggressive form of non-Hodgkin's
lymphoma (NHL).
For more information please see https://ehaweb.org and the Company's website:
https://www.bergenbio.com/investors/presentations/
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.